Nick Accomando joined Flatiron Health in December 2021 to lead the compliance and privacy team as the compliance and privacy officer. Flatiron Health is a health-tech company dedicated to improving cancer treatment and advancing research through healthcare provider solutions and real-world evidence. Accomando is licensed as an attorney in Massachusetts and is a certified information privacy professional. 

Prior to joining Flatiron, Accomando was an assistant general counsel on the global digital, technology, and privacy legal team at GlaxoSmithKline (GSK). In this role, Accomando headed up the global privacy function within legal and acted as the digital and technology attorney for research and development where he had enterprise responsibility for digital, technology, artificial intelligence (AI)/machine learning, data analytics, and data governance.  

Accomando joined GSK from IQVIA—a world leader in data, technology, and advanced analytics—where he was a senior legal director for Global Privacy and held responsibility for de-identified, pseudonymized, and anonymized data assets. Prior to IQVIA, Accomando was with IBM Watson Health as the global privacy counsel where he supported transactions, technology, AI strategy, data anonymization, data de-identification, and data stewardship frameworks across the company’s six divisions. Nick received a Bachelor of Arts in theology from Boston College in 2004 and a Juris Doctor from Loyola University New Orleans College of Law in 2007.  

Olalekan Ajayi, PharmD, MBA, is manager of Welch Cancer Center, Sheridan Memorial Hospital in Sheridan, Wyo., where he oversees both strategic and operational initiatives. Dr. Ajayi has led the oncology program at Sheridan Memorial for the past four years. He is a practicing oncology pharmacist and currently serves as an adjunct faculty member for the College of Health Sciences at the University of Wyoming. He is an active member of the Association of Community Cancer Centers (ACCC) and is an ACCC Board Member. 

Joe Alvarnas, MD, is a professor of hematology at City of Hope, and he supports AccessHope as its chief clinical advisor. Dr. Alvarnas also serves City of Hope as a clinician, caring for patients with HIV (human immunodeficiency virus)-related cancers and blood disorders, and as its vice president of Government Affairs. 

Al B. Benson III, MD, FACP, FASCO, is a professor of medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine in Chicago, Ill. He is also the associate director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center. 

Dr. Benson is a recipient of the American Society of Clinical Oncology (ASCO) Statesman Award (fellow of ASCO) and has been a member of and chaired several committees. Dr. Benson is the immediate-past chair of the Gastrointestinal Committee, ECOG-ACRIN deputy chair for Policy and Implementation, chair of the Data Monitoring Committee, co-chair of the Cancer Care Delivery Research committee, and a member of the NCI Rectal/Anal Task Force. He is chair of the International Rare Cancers Initiative, Anal Cancers Committee, and Small Intestinal Cancer Committee. In addition, Dr. Benson is a past president of the Illinois Medical Oncology Society and Association of Community Cancer Centers (ACCC), a member and past-chair of the Board of Directors of the National Comprehensive Cancer Network (NCCN), and board of directors member for the NCCN Foundation. He is the chair of both the NCCN Hepatobiliary Guidelines Panel and Colon, Rectal, and Anal Panel. Dr. Benson is a member of the Pancreatic Cancer and Neuroendocrine Panels. He is a past president of the International Society of Gastrointestinal Oncology. Dr. Benson is an executive committee member for the Patient Advocate Foundation and National Patient Advocate Foundation (president). Additionally, he is a medical advisory board member for Debbie’s Dream Foundation: Curing Stomach Cancer and Fight Colorectal Cancer. 

Jennifer Bires, MSW, LICSW, OSW-C, is the executive director of Life with Cancer and Patient Experience for the Inova Schar Cancer Institute. As executive director, she works to ensure that patients, survivors, and their family members have access to psychosocial care at no cost to help individuals cope with cancer, its treatments, and survivorship in the best possible way. She specializes in working with young adults who have been diagnosed with cancer, communicating around end-of-life concerns and sexual health, and has over a decade of experience running groups for people impacted by cancer. Bires oversees the Inova Arts and Healing program, ensuring patients have access to the arts as a modality for healing and as part of their treatment process. 

She earned her master’s degree from Washington University in Saint Louis, Mo.  She earned her bachelor’s degree from Clemson University. She was awarded the Oncology Social Worker of the Year in 2017 from the Association of Oncology Social Workers and is the past chair for the Board of Oncology Social Work. 

Courtney Bitz, LCSW, OSW-C, ACHP-SW, is the director of Clinical Social Work and Spiritual Care in the Department of Supportive Care Medicine at City of Hope. Bitz had strategic leadership in the implementation of the High-Performance Team and Staff Leadership Model for the Department of Supportive Care Medicine. 

Bitz has been in the field of psycho-oncology for over 18 years, specializing in evidence-based intervention modalities, concurrent program development, and organizational development. She spearheaded the development of the Couples Coping with Cancer Together Program, which provides strength-based education and support to patients diagnosed with cancer and their partners. The Couples Coping with Cancer Together Program has garnished international attention and, to our knowledge, is the only program of its kind in the country. 

She has been published in Psycho-Oncology, Oxford University Press, and Supportive Care in Cancer. She has presented her work at numerous international and national professional conferences, including the World Congress of Psycho-Oncology, American Psychosocial Oncology Society National Conferences, and Association of Oncology Social Work National Conferences. 

Lee Blansett, MBA, has been an active participant in the American healthcare system for thirty years. His research into health system organizations and market access topics includes extensive on-the-ground studies in the United States and European Union. Lee founded Proximity Health, LLC in 2016 to focus on the evolution of oncology providers in the U.S. 

Blansett’s early work included business strategy consulting for large health systems and internal consulting roles with Kaiser-Permanente and Stanford Children’s Hospital. His current work studies impact oncology care among integrated delivery networks, community oncology groups, and healthcare insurers.

His academic training includes an MBA from the Wharton School of the University of Pennsylvania and a bachelor’s degree in finance from Santa Clara University where he was a National Merit Scholar.  

Alexis Bortniker, JD, is a healthcare transactional lawyer in the San Diego office of Foley & Lardner LLP and is chair of the firm’s health care transaction group. Bortniker is a strategic advisor, working with healthcare providers, payers, private equity companies, and technology companies on joint ventures, mergers and acquisitions, payment structures, and complex business transactions. 

Bortniker has extensive experience in alternative payment models, population health management, risk-based reimbursement systems, and payer/provider alignment. She also has significant experience working with providers in Medicare Advantage and the Center for Medicare and Medicaid Innovation demonstration models. Bortniker advises emerging companies in navigating the move away from direct-to-consumer payment models to third-party payment strategies, including commercial payment, direct to employer, centers of excellence, and more. 

Steven L. D'Amato, BScPharm, has had experience in oncology practice for over 35 years. He has experience in both hospital and private practice settings. D’Amato has extensive knowledge in electronic health record implementation, drug utilization, value-based care, end-of-life care, and practice management. He most recently is a founding partner of Scientia Pharmacy Advisors, LLC. 

D'Amato was with the New England Cancer Specialists where he established their pharmacy program and became executive director. D’Amato is a past president of the Association of Community Cancer Centers (ACCC) and a past board member of the Community Oncology Alliance, where he now serves as a consultant. He is a member of the American Society of Clinical Oncology, Community Oncology Pharmacy Association, National Community Oncology Dispensing Association, and Hematology/Oncology Pharmacy Association.  

Cary Gross, MD, is professor of medicine and epidemiology at the Yale Schools of Medicine and Public Health. As director of the Cancer Outcomes Public Policy and Effectiveness Research Center at Yale University, the over-arching theme of Dr. Gross’ work is the disconnect between evidence generated from clinical research and the actual needs of people with cancer. To address this theme, Dr. Gross and his team apply state-of-the-art techniques to study the complex interplay between clinical decision-making and patient-centered outcomes, with an interest in providing actionable evidence to promote equitable access to high-value cancer care. 

James Hamrick, MD, MPH, is senior medical director at Flatiron Health—a healthcare technology and services company focused on accelerating cancer research and improving patient care. Dr. Hamrick is responsible for overseeing the clinical development of the OncoTrials and research software products, as well as providing clinical insight into the development of new features in OncoEMR, Flatiron’s electronic health record. 

Triple board-certified in internal medicine, medical oncology, and hematology, Dr. Hamrick also maintains a clinical practice at Kaiser Permanente in Atlanta, Ga., where he previously served as chief of medical oncology and hematology. Dr. Hamrick serves on the board of the Georgia Center for Oncology Research and Education. 

John Hennessy, MBA, CMPE, is senior vice president, strategist for Valuate Health Consultancy. Valuate works with clients to understand how to best ensure access for their products and services in the complex United States healthcare system. His oncology chops were earned in community and academic practices, in both physician office and hospital settings. 

Hennessy was the executive director of the Kansas City Cancer Centers, a US Oncology affiliate, and one of the first oncology practices in the nation to adopt clinical pathways.  He also served as vice president of Operations for Sarah Cannon, the oncology service line of HCA Healthcare, and helped hospitals develop and manage hematology and cancer service lines. 

He was an American Society of Clinical Oncology (ASCO) member and volunteer, having served on the Clinical Practice Committee, Practice Guidelines Implementation Network, and State Affiliates Council. Hennessy had the privilege of working on ASCO’s Payment Reform Task Force that developed the Patient-Centered Oncology Payment (P-COP) alternative payment model. He also worked with ASCO as a consultant with the Practice Support group, helping oncology practices ensure patient-focus and value-based care readiness. He is the vice president of the Board of Directors for the Young Survival Coalition. 

Andrew Hertler, MD, FACP, is the chief medical officer of New Century Health and is responsible for the advancement of the company’s clinical quality initiatives, value-based strategies, and utilization management policies and operations. A board-certified oncologist who left clinical practice in 2014, he is a nationally recognized leader in oncology clinical practice. 

Prior to joining the New Century Health in 2014, Dr. Hertler was the administrative medical director for physician practices at Maine General Medical Center, and he was the medical director of the Harold Alfond Center for Cancer Care in Augusta, Maine. Earlier in his career, Dr. Hertler was assistant professor of medicine in hematology/oncology at the Louisiana State University Medical School. Dr. Hertler is a past member of several American Society of Clinical Oncology committees, including the Clinical Practice, Quality of Care, and Payment Reform Committees. He is also a past president of the Northern New England Clinical Oncology Society. 

Dr. Hertler received his medical degree from the University of Michigan and completed his residency in internal medicine at the University of Michigan’s affiliated hospitals. He later completed a fellowship in medical oncology/hematology at Duke University Medical Center. He received his bachelor’s degree in chemistry with highest honors from Dartmouth College. 

Ira Klein, MD, MBA, FACP, is the vice president of Medical Affairs for Payor Relations for Tempus—a data driven precision medicine company that provides the world’s largest library of clinical and molecular data. Most recently, prior to this new position, Dr. Klein was the chief medical officer of Health New England, leading plans and efforts in medical management, contracting, network integrity, and quality and analytics. Dr. Klein has a personal interest in health information technology (HIT) and data security, previously certified in the medical HIT area. 

Previously, he was the leader and senior director of Healthcare Quality Strategy in the Strategic Customer Group of Johnson & Johnson Health Care Systems Inc. for five years, building a new quality strategy capability for the Janssen Biotech Inc. brands. Prior to that, Dr. Klein was the national medical director for Clinical Thought Leadership, chief of staff to the chief medical officer, and founded the Oncology Solutions team that created pathways and medical home value-based arrangements at Aetna. He also developed novel wellness and benefit design programs in the large employer segment of Aetna's national accounts business. 

Dr. Klein’s early career included being assistant chief medical officer of Bayshore Community Health Systems for three years (working in all aspects of inpatient and outpatient business), chief medical officer of Elderplan for two years (serving the frail elderly in New York City), and practicing internal medicine for seven years at Robert Wood Johnson Medical School as well as being assistant professor in Internal Medicine.  Dr. Klein is an Alpha Omega Alpha graduate of Robert Wood Johnson Medical School (RWJMS) and completed residency training at Brown University and RWJMS/University of Medicine and Dentistry of New Jersey. He received his MBA from Rutgers School of Business, and he remains board certified in internal medicine.  

Michael Kolodziej, MD, FACP, is senior advisor at ADVI Health. He joined ADVI in October 2017. Dr. Kolodziej practiced oncology with New York Oncology from 1998 to 2013. During this time, he also was chairman of the US Oncology Network’s Pharmacy and Therapeutics Committee. In this role, he helped direct the implementation of the US Oncology Network’s clinical pathways initiative. 

Dr. Kolodziej joined Aetna in January 2013, as national medical director of Oncology Solutions. While at Aetna, he directed the company's oncology programs and was the architect of the Aetna Oncology Medical Home. Dr. Kolodziej joined Flatiron Health in July 2016 as national medical director, Managed Care Strategy. He is a fellow of the American College of Physicians. 

Tynan O. Kugler, MBA, MPH, CVA, is consulting principal at PYA P.C., and her experience includes performing fair market value compensation analyses as well as valuations of medical practices and ancillary service lines for a variety of physician and hospital transactions. Additionally, her experience includes valuations specific to the life sciences industry, including key opinion leader compensation and fee-for-service arrangements. Kugler also conducts provider needs analyses and strategic market assessments. 

She has more than two decades of healthcare consulting experience, and prior to rejoining PYA in 2007, she spent several years assisting community hospitals/healthcare systems, academic medical centers, and physician groups with strategic planning related to the development of coordinated, comprehensive cancer programs. Kugler has specific expertise in medical, radiation, and surgical oncology and provides various related valuation and consulting services specific to these specialties. She obtained her MBA from the Goizueta Business School and her MPH from the Rollins School of Public Health at Emory University. 

Harlan Levine, MD, is president of strategy and business ventures for City of Hope.  In this role, he is accountable for strategy, innovation and growth, drug commercialization, payer strategies, and the Center for International Medicine. Dr. Levine also serves as Chairman of the Board of AccessHope, City of Hope’s subsidiary focused on serving the employer market and making leading-edge cancer care available to all regardless of geography. Dr. Levine is board certified in internal medicine. 

Prior to City of Hope, Dr. Levine held executive roles at United Health Group, Towers Watson, and Anthem, Inc. He currently serves as a board member for Active Life Scientific, BioScienceLA, Reimagine Care, and Vida Health, and he is a member of Keck Graduate Institute’s Board of Trustees. Dr. Levine is a long-term strategic advisor to the founder/chairman of the board for Quantum Health, a member of the Accessibility and Affordability Working Group for California Institute for Regenerative Medicine. He is also a workgroup fellow for Health Evolution Forum’s New Models of Care Delivery. He received his undergraduate degree from Harvard College and medical degree from University of California San Francisco.  

Mark Liu, MHA, is the director of Strategic Initiatives for the oncology service line at the Mount Sinai Health System—an eight-hospital integrated health system in all five boroughs of New York City. He works closely with senior leadership to develop long-term strategy, while working collaboratively on critical projects in clinical quality, alternative payment models, new technologies, and process improvement. 

Liu first joined Mount Sinai as part of a team to facilitate the build of Mount Sinai Health Partners, an entity advancing population health within the health system. Prior to this, Mark managed ambulatory care operations at Memorial Sloan Kettering Cancer Center across nine different solid and hematologic cancers during his eight-year tenure. 

He graduated with a Master of Healthcare Administration from the Mailman School of Public Health at Columbia University and a Bachelor of Science double major in Integrated Neuroscience and Sociology from Binghamton University. Liu was selected as a 2008 fellow of the Fellowship for Emerging Leaders in Public Service at New York University's Robert F. Wagner Graduate School of Public Service. He also recently completed the 2021 Association of Cancer Executives Administrative Fellowship Program. 

Paul Martino is the co-founder and chief growth officer at VillageMD, a leading provider of healthcare for organizations moving toward a primary care-led, high-value clinical model. His responsibilities include identifying and addressing market needs, growing the base of affiliated primary care physicians, developing strategic partnerships, and expanding the reach of the VillageMD brand. A 30-year veteran of the healthcare industry, Martino has driven growth and fostered innovation as an executive for health plans and consultancies. 

Prior to VillageMD, Martino was senior vice president of Clinical Strategy and Innovation at Anthem/WellPoint, the second largest health plan in the United States.  He was instrumental in architecting Anthem’s payment innovation strategy, developing its patient-centered primary care model, and establishing value-based contracts with the company's primary care physician network.

Barbara L. McAneny, MD, FASCO, MACP, is the first oncologist to be elected president of the American Medical Association. In 2012, Dr. McAneny received a $19.8 million award from the Centers for Medicare and Medicaid Innovation to test how oncology private practices could provide cancer patients better care at a lower cost. This COME HOME (for Community Oncology Medical Home) award later helped form Medicare’s Oncology Care Model. Currently, Dr. McAneny is working on a project called MASON to use data science techniques to create accurate target prices for cancer treatment. 

Dr. McAneny is a board member of the Community Oncology Alliance and board chair of the National Cancer Care Alliance, which she founded to help independent oncology practices remain independent by sharing resources and best practices. 

Dr. McAneny co-founded New Mexico Oncology Hematology Consultants Ltd. in 1987. A managing partner since 1999, she built New Mexico Cancer Center, which provides outpatient medical and radiation oncology care and imaging in Albuquerque and the underserved area of Gallup. She also founded the New Mexico Cancer Center Foundation, which provides grants to help patients with non-medical expenses.  

Krista Nelson, MSW, LCSW, OSW-C, BCD, is a trained oncology social worker and has worked in clinical research and program management roles within Providence Health and Services for the past 21 years. Most recently, Krista joined the compassion team as a program manager, bringing her clinical expertise to work on creating supportive infusions of compassion to caregivers. She is also the president of the Association of Community Cancer Centers. 

Nelson is a past president of the board of directors of the Association of Oncology Social Work and past invited director of the American Psychosocial Oncology Society. She is also an invited director on the board of directors for the National Accreditation Program for Breast Centers. 

Nelson has spoken at local and national conferences on issues like survivorship, palliative care, distress screening, and children who have a parent with cancer. In 2015, Nelson was named a finalist of the Schwartz Center Compassionate Caregiver of the Year award and recipient of an ACCC Innovator Award. She has been a volunteer facilitator at retreats for women with breast cancer and at camps and programs that support grieving children. Since 2009, Nelson has volunteered annually on medical relief teams in Haiti. 

Melynda Ozan, MLIS, has been a medical/health sciences librarian since 2011. In her current role as consumer health librarian at Levine Cancer Institute, she directs a network-wide health literacy and patient education initiative to bring clear, understandable information to patients with cancer and their caregivers. Her current areas of interest include adult learners and the intersection of health literacy and information literacy. 

She earned her Master of Library and Information Studies degree from the University of North Carolina at Greensboro. 

Kimberly Peairs, MD, FACP, is an associate professor of medicine at the Johns Hopkins University School of Medicine in the Department of Medicine (division of General Internal Medicine) and the Sidney Kimmel Comprehensive Cancer Center. 

She is the vice chair for Clinical Affairs and Ambulatory Medicine for the Johns Hopkins Department of Medicine. Dr. Peairs is a clinician educator and ambulatory leader with an active primary care practice that has a focus on cancer survivorship.  She was the founder of the Johns Hopkins Primary Care for Cancer Survivors program, with an interest in the transitions of care and care coordination that are necessary for these patients.  Dr. Peairs has worked as part of a multidisciplinary team at Johns Hopkins to develop care guidelines for patients with cancer and her research investigates the co-morbidities that impact patients as well as the importance of primary care for these patients. She has published and delivered numerous educational seminars on these topics to educate medical trainees and practitioners in a variety of care settings.   

Robin N. Richardson, MA, is the assistant director of Care Delivery Transformation and Community Engagement at Dell Medical School’s Livestrong Cancer Institutes at the University of Texas at Austin, where she codesigns, implements, and evaluates supportive care programs with patients, survivors, and loved ones. 

Richardson has worked in Texas and D.C. for the past 15 years on care delivery transformation, large-scale implementation, and strategic planning. She earned a master’s degree in International Human Rights with a focus on global health from the University of Denver, and she serves on the board of Ground Floor Theatre and the Moving Beyond Cancer Collaborative. Her work is dedicated to public service, social justice, and exploring the intersection of health and the arts. 

Candice Roth, MSN, RN, CENP, is an assistant vice president with operational, nursing, quality, nurse navigation, outreach, and disparities responsibilities at Levine Cancer Institute. She is also president of the Greater Charlotte Area Oncology Nursing Society. 

She began her career 19 years ago as a nurse in critical care and quickly found her niche in oncology. Roth’s passion for nursing has only increased through the years as she has grown into a nurse administrator, leader, and mentor. She is an active member of the American Organization of Nurse Executives, American College of Healthcare Executives, American Nurses Association, National League for Nursing, and American Society of Blood and Marrow Transplantation. Roth has a Bachelor of Science in nursing from Avila University and a Master of Science in Nursing from the University of Phoenix. 

Deirdre Saulet, PhD, is an expert partner at The Advisory Board, an independent subsidiary of Optum. She has served as an oncology subject matter expert, overseeing studies on value-based payment, financial toxicity, patient experience, growth strategy, and more. Additionally, Dr. Saulet enjoys convening and facilitating conversations with stakeholders across the industry on some of today's most pressing topics, including the future of infusion, precision medicine, and care delivery transformation. Dr. Saulet received her PhD in immunology from Duke University.  

Rebekkah Schear, MIA, is pioneering the strategic development, operations, and implementation of clinical cancer care at the Livestrong Cancer Institutes at Dell Medical School. Under the leadership of Dr. S. Gail Eckhardt, Schear and the team are building a new model of patient-centered cancer care and launching the CaLM Clinic—a comprehensive, clinical, and supportive outpatient clinic with wraparound care that offers practical, emotional, physical, social, spiritual, and financial support to patients and their caregivers. Schear and her colleagues are also building the first comprehensive young adult cancer clinic in the Austin area.  

Schear is leading a community-wide engagement initiative for the Livestrong Institutes, ensuring that all strategies and services are co-designed with patients, caregivers, and the cancer community. Under her leadership, Austin launched a new coalition (Austin Cancer Support Coalition) in 2017 to organize and mobilize the central Texas cancer community to implement community-wide initiatives, services, research, and education for patients, survivors, families, providers, and caregivers. Over the last 10 years, Schear has designed and implemented more than a dozen community-based, national, and global cancer programs to improve the quality of life for cancer survivors and their families and to educate and engage healthcare providers.  

During her tenure at Livestrong Foundation, Schear led the foundation’s implementation of seven international cancer control programs throughout Latin America, Africa, and Asia. Her work focused on building capacity of cancer non-governmental organizations to lead and implement patient-driven policy initiatives and addressing cancer stigma through improving knowledge and changing attitudes by empowering survivors to share their cancer stories.  

Schear holds a Bachelor of Arts in mass communications from the University of California, Los Angeles and a Master of International Affairs in economic and political development from Columbia University. Her career has focused on the intersection of cancer care delivery, global health, and advocacy. 

Bhavesh Shah, RPh, BCOP, is a board-certified oncology pharmacist and senior director of Specialty and Hematology/Oncology Pharmacy Services at Boston Medical Center Health System. In this role, he is responsible for the clinical and operational efficiency of the cancer center, specialty pharmacy, and various ambulatory specialty areas. Shah also oversees clinical support for specialty programs for a managed care Medicaid plan with over 400,000 lives covered. 

He has research experience in cancer-related anorexia and cachexia syndrome, prevention of chemotherapy-induced nausea and vomiting, treatment of iron deficiency anemia, and digital adherence technology, immune thrombocytopenia, purpura, biosimilars, and inflammatory bowel disease. Shah is a reviewer for the Annals of Pharmacotherapy and has published articles in the Journal of Oncology Pharmacy Practice, Supportive Care in Cancer, and Biology of Blood and Marrow Transplantation.  He has presented both nationally and internationally in the specialty pharmacy arena, 340B Drug Pricing Program, and field of hematology/oncology pharmacy. 

Shah earned a Bachelor of Science in pharmacy at Massachusetts College of Pharmacy and Health Sciences, subsequent to receiving a biochemistry degree from Loyola University Chicago. 

Mark L. Sobczak, MD, is the clinical director of Radiation Oncology at the Fox Chase Cancer Center in Philadelphia, Penn. Dr. Sobczak’s practice background includes experience in military medicine, radiation oncology private practice, and within academic medical centers. He has been a Cancer Center Business Summit advisory board member for the past seven years. 

Dr. Sobczak is a distinguished graduate of the United States Naval Academy and the Uniformed Services University of the Health Sciences. He spent 24 years as a U.S. Navy pilot and radiation oncologist. 

Jennifer L. Urban (formerly Rathburn) is a partner with Foley & Lardner LLP. She focuses her practice on counseling clients on data protection programs, data incident management, breach response and recovery, monetization of data, and other privacy and security issues. Urban is a founder of the Midwest Cyber Security Alliance and has a deep understanding of the complex risk, operational, and legal issues companies must address to maintain the confidentiality of, access to, and integrity of their data. 

She is a member of the firm’s Technology Transactions & Outsourcing; Privacy Security & Information Management; and Environmental, Social, and Corporate Governance practice groups. She routinely helps clients prepare for and respond to data security incidents, from preparing incident response plans and advising on cybersecurity programs to handling the breach notification response process. Her depth of experience in this area and her collaboration with information technology, risk, forensic, dark web, communications/public relations, and other data experts provides a multi-disciplinary, practical approach to client issues. Additionally, Urban guides clients in all aspects of preparing for and maintaining compliance with American and global privacy and data security laws, including the California Consumer Privacy Act of 2018 and the European Union’s General Data Protection Regulation. Such efforts include conducting readiness assessments, performing data mapping and inventory, reviewing and revising privacy and data security and incident response policies and plans, updating customer- and employee-facing privacy and consent notices as well as third-party vendor templates and agreements, evaluating the appointment of a data protection officer, and educating and training board members, staff, and other key stakeholders. 

Nathan H. Walcker, MBA, joined Florida Cancer Specialists and Research Institute in 2019 as the chief financial officer, bringing more than a decade of diverse healthcare, physician services, and corporate finance expertise with him. He was appointed chief executive officer in 2020. 

Previously, Walcker served as a key member of Bank of America Merrill Lynch’s Global Healthcare Investment Banking group in New York, advising the firm’s public and emerging growth healthcare clients and leading private equity firms. Walcker began his career on Wall Street on the Merrill Lynch trading floor in New York and went on to assume increasing responsibilities as an investment banker and strategic advisor to corporations, entrepreneurs, and public company boards. Walcker earned an MBA from Columbia Business School and a bachelor’s degree in economics from Columbia University. 

Lauren Wallner, PhD, MPH, is an associate professor of Internal Medicine and Epidemiology at the University of Michigan and co-Leader of the Cancer Control and Population Sciences Program at Rogel Cancer Center. Dr. Wallner is also a faculty member in the Cancer Surveillance and Outcomes Research Team (CanSORT) and Institute for Healthcare Policy and Innovation. She is a cancer epidemiologist and health services researcher by training. 

Her research program focuses on improving the quality, delivery, and equity of cancer care. Dr. Wallner’s research experience spans the cancer continuum and includes multiple cancer sites. She has conducted several studies to understand the determinants, outcomes, and utilization of health services associated with cancer. She has expertise in the design, evaluation, and implementation of interventions to improve cancer care. Dr. Wallner also has experience conducting analyses of large healthcare databases and population-based survey studies of patients with cancer, care partners, and physicians using cancer registries. Her work has been continually funded by the National Institutes for Health, American Cancer Society, and industry partners. She is passionate about mentoring the next generation of cancer care delivery researchers. 

Dr. Wallner received her BS, MPH, and PhD degrees at the University of Michigan and completed her post-doctoral training in cancer health services research at Kaiser Permanente Southern California and the University of California Los Angeles.  

Emily Wampfler, MS, MBA, is the senior director of Product Management for the Mayo Clinic Platform—a new business unit within Mayo Clinic. She has been involved in the platform’s development from >span class="NormalTextRun SCXW108032210 BCX0"> beginning, serving as an interim leader to coordinate cross-functional teams to advance the platform’s strategy, business model, and partner relationships.  

Prior to her role with the Mayo Clinic Platform, Wampfler held various positions in Mayo’s Department of Business Development within the Mayo Clinic Ventures and Corporate Development divisions, where she evaluated the patentability of new technologies and strategic business opportunities ranging from partnerships to acquisitions. She has a background in science, focusing on Alzheimer’s disease as a research laboratory technologist early in her career. 

Wampfler received her bachelor’s degree in biochemistry and molecular biology from the University of Wisconsin-Eau Claire and master’s degree in cell biology and genetics from the Mayo Clinic Graduate School of Biomedical Sciences. In addition, she is a 2021 Master of Business Administration graduate from the Carlson School of Management at the University of Minnesota. 

Adria E. Warren, JD, is a partner and healthcare lawyer with Foley & Lardner LLP, where she advises clients on mergers, acquisitions, affiliations, and strategic transactions, including the formation of provider groups, networks, alliances, and joint ventures. In addition, Adria counsels entrepreneurs and established companies on a wide range of day-to-day legal and business issues, including corporate governance, securities laws compliance, tax, and employment matters. She is a member of the Health Care and Technology Industry teams as well as the Transactional & Securities, Private Equity & Venture Capital, and International practice groups. 

Phil Watts, JD, is a founding member of OneOncology, where he serves as general counsel. Phil has nearly three decades of experience in the healthcare industry. 

Prior to founding OneOncology, Watts was general counsel of Molecular Health Inc., a computational biomedicine company. His previous experience also includes several prominent positions at US Oncology, Inc., including executive vice president and general counsel and secretary. In those capacities, Watts led the company’s legal, governmental affairs, and strategic planning activities and served on the company’s executive committee. Phil received his law degree from Harvard Law School and his bachelor’s degree from the University of Tulsa. 

Lalan Wilfong, MD, is the vice president of Payer Relations and Practice Transformation for McKesson. Working with over 2,000 providers across the nation, Dr. Wilfong works to align value-based payment reform with practice transformation and quality cancer care with payment models. In addition, he is a medical oncologist/hematologist with Texas Oncology, PA. 

Dr. Wilfong’s current research interest focuses on aligning quality patient care and value in the community setting. Other areas of focus include improving patient-provider communications, enhancing end-of-life care, integrating pathways into clinical practice, and improving patient satisfaction. Dr. Wilfong co-chairs the Community Oncology Alliance Payment Reform Committee to help community oncology practices navigate the complex world of value-based payment reform. 

He earned his MD from the University of Texas Southwestern Medical School in Dallas, Texas, in 1997. He completed his internship and residency in internal medicine at the University of Texas Southwestern Medical School in 2000. In 2003, Dr. Wilfong completed a fellowship at the University of Texas Southwestern Medical School in hematology and medical oncology. He earned his BS in mathematics at Texas Tech University in Lubbock, Texas, in 1993.